Glucocorticoid therapy in patients with sepsis shock
Sepsis poses a significant global public health challenge,drawing widespread attention due to its high morbidity and mortality rates.It typically arises from an immune response imbalance triggered by infection,which can progress to septic shock in severe cases.The efficacy of glucocorticoids as anti-inflammatory drugs for treating septic shock remains controversial.This article reviews the research literature on glucocorticoid treatment for septic shock over the past five years,encompassing perspectives on treatment approaches,mechanisms of ac-tion,selection of drug types and dosages,optimal timing of administration,laboratory tests guiding glucocorticoid therapy for septic shock management,and analysis of associated adverse reactions.Our findings indicate that a considerable portion of the literature leans towards considering glucocorticoid therapy effective and recommends u-sing hydrocortisone at doses ranging from 200 to 400 mg per day for treatment cycles lasting typically 4 to 7 days.Adverse reactions such as gastrointestinal bleeding and secondary infections may occur during treatment.For pa-tients with inadequate therapeutic response,laboratory tests(such as inflammatory factors and genetic testing)could be considered to guide further management decisions.The conclusion of this article can offer valuable in-sights for clinicians.However,it is important to acknowledge the limitations of this conclusion.Firstly,some references fail to differentiate between sepsis and septic shock.Secondly,there is a scarcity of publications ad-dressing the types of glucocorticoids,optimal timing for administration,and laboratory tests that can guide the treatment of septic shock.Therefore,additional research is necessary to further validate the conclusions drawn in this study.
NETL
NSTL
万方数据
